How might deucravacitinib fit into the treatment pathway for patients with SLE?

During the Lupus Hub Steering Committee meeting, key opinion leaders discussed how deucravacitinib might fit into the...

Baricitinib in SLE: Results from the phase III SLE-BRAVE trials

Outcomes in patients with systemic lupus erythematosus (SLE) remain poor, and trials for new drugs in SLE often have negative results....

Editorial theme | Treat-to-target in SLE

The treat-to-target (T2T) strategy is examined, along with a discussion of the advantages and disadvantages of its use when managing patients with SLE, in this...

Impact of medium-to-high glucocorticoid dose on the risk of bloodstream infections in patients with SLE

Here, we summarize a recent article by Kim et al. on incidence rates of BSIs and associated risk...

Using the EULAR/ACR criteria to assess organ damage in patients with SLE and LN

Here, we evaluate EULAR/ACR criteria as a prognostic tool for patients with SLE and explore the relationship between...

What do HCPs need to know about LN and the prevention of progression to ESRD?

The Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What do HCPs need to...

Assessing laboratory markers as biomarkers for renal flare in patients with SLE

Here, we summarize data presented from four phase III trials assessing laboratory markers as biomarkers for renal flare...

Editorial theme | Impact of SLE and LN on patients’ QoL and body image

We examine the impact of lupus nephritis and systemic lupus erythematosus on quality of life and body image disturbance in this...

Increased risk of cardiovascular disease in patients with cutaneous lupus erythematosus

A summary results from a large, nationwide cohort study by Shams‑Eldin, et al, published in Clinical...

Litifilimab in patients with cutaneous lupus erythematosus

To assess whether litifilimab is effective for the treatment of SLE and CLE, a two-part phase II study was performed with the findings...

Management of general systemic lupus erythematosus

This article summarizes the 2019 recommendations for the management of SLE, along with recent developments from subsequent clinical trials.